CTSO CYTOSORBENTS CORP revenue, earnings and financials
For the quarter ended June 30, 2026, CYTOSORBENTS CORP reported revenue of $9.63M (up 0.2% from a year earlier), net income of −$4.42M and diluted EPS of −$0.07; over the last four quarters revenue was $37.2M and net income −$18.2M; for the fiscal year ended December 2025 revenue was $37.1M, up 4.1% on the year before.
CTSO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $37.1M, gross profit $26.5M, operating income −$14.7M, net income −$8.20M (margin -22.1%), EPS −$0.13
- Fiscal year ended Dec 2024: revenue $35.6M, gross profit $24.9M, operating income −$16.5M, net income −$20.7M (margin -58.2%), EPS −$0.38
- Fiscal year ended Dec 2023: revenue $31.1M, gross profit $22.0M, operating income −$31.9M, net income −$29.2M (margin -94.1%), EPS −$0.65
- Fiscal year ended Dec 2022: revenue $34.7M, gross profit $20.7M, operating income −$31.5M, net income −$32.8M (margin -94.6%), EPS −$0.75
- Fiscal year ended Dec 2021: revenue $43.2M, gross profit $32.1M, operating income −$22.7M, net income −$24.6M (margin -56.9%), EPS −$0.57
CTSO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $9.63M (up 0.2% year over year), net income −$4.42M, EPS −$0.07
- Quarter ended Mar 31, 2026: revenue $8.86M (up 1.6% year over year), net income −$5.13M, EPS −$0.08
- Quarter ended Dec 31, 2025 (from the annual report): revenue $9.23M (up 0.9% year over year), net income −$5.50M, EPS −$0.09
- Quarter ended Sep 30, 2025: revenue $9.49M (up 10.1% year over year), net income −$3.17M, EPS −$0.05
- Quarter ended Jun 30, 2025: revenue $9.62M (up 8.8% year over year), net income $1.95M, EPS $0.03
- Quarter ended Mar 31, 2025: revenue $8.73M (down 2.9% year over year), net income −$1.48M, EPS −$0.02
- Quarter ended Dec 31, 2024 (from the annual report): revenue $9.15M (up 5.6% year over year), net income −$7.57M, EPS −$0.14
- Quarter ended Sep 30, 2024: revenue $8.61M (down 2.2% year over year), net income −$2.77M, EPS −$0.05
- Quarter ended Jun 30, 2024: revenue $8.84M (down 6.1% year over year), net income −$4.29M, EPS −$0.08
- Quarter ended Mar 31, 2024: revenue $8.99M (down 4.9% year over year), net income −$6.09M, EPS −$0.11
- Quarter ended Dec 31, 2023 (from the annual report): revenue $8.67M (down 7.7% year over year), net income −$6.57M, EPS −$0.12
- Quarter ended Sep 30, 2023: revenue $8.81M (up 8.6% year over year), net income −$9.19M, EPS −$0.21
- Quarter ended Jun 30, 2023: revenue $9.42M (up 10.9% year over year), net income −$6.15M, EPS −$0.15
- Quarter ended Mar 31, 2023: revenue $9.45M (up 8.7% year over year), net income −$7.33M, EPS −$0.17
- Quarter ended Dec 31, 2022 (from the annual report): revenue $9.39M (down 12.9% year over year), net income −$766K, EPS −$0.02
- Quarter ended Sep 30, 2022: revenue $8.11M (down 16.9% year over year), net income −$12.2M, EPS −$0.28
- Quarter ended Jun 30, 2022: revenue $8.50M (down 29.3% year over year), net income −$10.9M, EPS −$0.25
- Quarter ended Mar 31, 2022: revenue $8.69M (down 18.0% year over year), net income −$8.97M, EPS −$0.21
- Quarter ended Dec 31, 2021 (from the annual report): revenue $10.8M, net income −$9.31M, EPS −$0.25
- Quarter ended Sep 30, 2021: revenue $9.76M, net income −$6.41M, EPS −$0.15
CTSO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$14.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$21.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$28.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$14.0M, share buybacks n/a
CTSO balance sheet
- Jun 30, 2026: cash $4.41M, total assets $38.0M, total liabilities $38.7M, shareholders' equity −$751K, long-term debt $3.09M
- Mar 31, 2026: cash $4.81M, total assets $40.6M, total liabilities $38.4M, shareholders' equity $2.19M, long-term debt $10.3M
- Dec 31, 2025: cash $6.25M, total assets $44.2M, total liabilities $38.3M, shareholders' equity $5.90M, long-term debt $16.7M
- Sep 30, 2025: cash $7.54M, total assets $45.8M, total liabilities $36.7M, shareholders' equity $9.02M, long-term debt $14.6M
- Jun 30, 2025: cash $10.2M, total assets $48.0M, total liabilities $36.4M, shareholders' equity $11.6M, long-term debt $14.4M
- Mar 31, 2025: cash $11.6M, total assets $50.8M, total liabilities $36.2M, shareholders' equity $14.5M, long-term debt $14.2M
- Dec 31, 2024: cash $3.28M, total assets $47.4M, total liabilities $36.3M, shareholders' equity $11.1M, long-term debt $14.0M
- Sep 30, 2024: cash $5.69M, total assets $47.8M, total liabilities $34.7M, shareholders' equity $13.4M, long-term debt $13.8M
What is CTSO's revenue?
CYTOSORBENTS CORP reported $37.2M of revenue over its last four quarters, through June 30, 2026.
Is CTSO profitable?
No. CYTOSORBENTS CORP lost $18.2M over the last four quarters.
What is CTSO's EPS?
Diluted earnings per share over the last four quarters were −$0.29; −$0.07 in the latest quarter.